Welcome to our dedicated page for DRNA news (Ticker: DRNA), a resource for investors and traders seeking the latest updates and insights on DRNA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DRNA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DRNA's position in the market.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced that Novo Nordisk has nominated its first candidate for treatment of liver-related cardiometabolic diseases under their collaboration. This nomination is a significant milestone for Dicerna, demonstrating the effectiveness of their GalXC™ RNAi platform technology. Over the past year, the partnership has led to the identification and validation of multiple therapeutic candidates, showcasing the productive nature of their relationship.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced the approval of inducement grants totaling 23,350 stock options and 5,675 restricted stock units (RSUs) for three new employees, effective Jan. 4, 2021. The stock options have an exercise price of $22.07 per share and vest over four years, with 25% vesting after one year. The RSUs vest similarly with 25% on Dec. 15, 2021. These grants align with Nasdaq Rule 5635(c)(4) and support Dicerna's mission to develop RNA interference therapies targeting various diseases.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has completed enrollment in its PHYOX™2 pivotal clinical trial for nedosiran, targeting all three types of primary hyperoxaluria (PH). This milestone indicates significant progress despite COVID-19 challenges. The trial aims to evaluate the safety and efficacy of nedosiran as a once-monthly treatment. Top-line results are anticipated in mid-2021, with plans for a New Drug Application (NDA) submission in Q3 2021. PHYOX2 includes 35 participants from 11 countries, focusing on patients aged six and older with PH1 or PH2.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced the approval of inducement grants of stock options for 30,575 shares and 8,750 restricted stock units (RSUs) to six new employees, effective December 1, 2020. The stock options have an exercise price of $24.76, vesting over four years, while the RSUs vest similarly with 25% on December 15, 2021. These grants comply with Nasdaq listing Rule 5635(c)(4). Dicerna focuses on RNA interference therapeutics aimed at treating various diseases, leveraging its GalXC™ technology platform.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced positive results from its Phase 1 trial of RG6346, a GalXC™ RNAi therapeutic for chronic hepatitis B virus (HBV) infection, in collaboration with Roche. The updated data showed significant and sustained reductions in hepatitis B surface antigen (HBsAg) levels, with 92% of participants experiencing notable declines. Additionally, RG6346 demonstrated a favorable safety profile. The promising results suggest RG6346 could be a crucial element in combination therapies aimed at achieving functional cures for chronic HBV patients.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced the acceptance of the Investigational New Drug Application (IND) by the FDA for LY3561774, marking a significant milestone from its collaboration with Eli Lilly. This achievement triggers a $10 million payment to Dicerna and allows Lilly to begin a Phase 1 clinical trial aimed at treating a cardiometabolic disease. The ongoing partnership, established in 2018, may yield additional milestone payments and product sales royalties, reflecting the potential of Dicerna's RNA interference technology in therapeutic development.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced that CEO Douglas M. Fambrough will participate in two upcoming investor conferences. The Stifel Virtual Healthcare Conference is scheduled for Nov. 18, 2020, at 3:20 p.m. ET, followed by the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Dec. 1, 2020, at 10:05 a.m. ET. Live audio webcasts of both events will be available on the Dicerna website, with archived replays accessible afterward. Dicerna focuses on RNAi therapeutics to target disease-causing genes through its proprietary technology platform, GalXC™.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced that Dr. Marc Abrams will present an update on their early-stage development of extrahepatic RNAi therapeutics at the TIDES Europe conference from Nov. 11-13, 2020. The presentation will feature nonclinical data showcasing mRNA knockdown activity in multiple extrahepatic tissues using Dicerna's proprietary RNAi technology. Dicerna continues to expand its investigational RNAi therapies beyond the liver, aiming to target a broader range of diseases. The company has established collaborations with leading pharmaceutical companies to enhance its research.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) has announced inducement grants of stock options for 40,950 shares and 11,650 restricted stock units to nine new employees, effective November 2, 2020. The stock options have an exercise price of $21.15 and vest over four years, with a 10-year term. The RSUs also vest over four years, with the first portion vesting on December 15, 2021. These grants comply with Nasdaq listing Rule 5635(c)(4) and are part of Dicerna's strategy to support its RNAi therapeutic development efforts.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced updated data for RG6346, a GalXC™ RNAi therapeutic aimed at treating chronic hepatitis B virus (HBV) infection. This data will be presented at The Liver Meeting® 2020 from Nov. 13-16. The findings suggest RG6346 is safe, well-tolerated, and can lead to significant reductions in serum HBsAg levels, indicating its potential as a treatment option. The Phase 1b-2a trial highlights RG6346's promise in achieving functional cures compared to existing therapies.
